ESPCI web site
HIV vaccine development and the selection of neutralizing HIV Antibodies
The project aims to screen HIV envelope protein variants displayed proteins for catalytic activity using an “ad hoc” developed droplet-based microfluidic system.
In particular the trimeric surface envelope glycoprotein Env (gp120/gp41), which targets HIV-1 entry by interacting directly with cell CD4 receptor and co-receptors, will be the main targets. At first different gp120/gp41Env variants will be screened for stability of neutralizing epitopes and absence of non-neutralizing epitopes. HIV Env variants will be also evolved and screened using this system.
This program is funded by the International AIDS Vaccine Initiative